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Introduction
Patients with an isolated secundum atrial septal defect 
(ASDII) have benefited from diagnostic and therapeutic 
advancements over the past decades. They can be diagnosed 
and treated early in life, but frequently remain asymptomatic 
and unrecognised well into adulthood. Consequently, these 
patients form a heterogeneous adult population regarding 
disease burden, risk of complications and required medical 
surveillance and treatment. In this paper we review the diag-
nosis and management of ASDII in adults, with attention to 
recent developments. We focus on the aspects relevant to 
the decision regarding defect closure, its benefits and limi-
tations and the necessity for continued follow-up, that are 
important to the general cardiologist confronted with and 
caring for these patients.
Prevalence
Atrial septal defect (ASD) is a common congenital heart 
defect, with an estimated birth prevalence of 1.6 per 1000 
live births and a 97 % probability of survival into adulthood 
[1, 2]. ASDII constitutes about 75 % of these defects, has 
a female predominance of approximately 2:1, and is fre-
quently diagnosed in adulthood [3, 4].
Genetic factors
Several genetic syndromes, such as Down, Holt-Oram and 
Noonan, are associated with ASDII [5]. However, most 
secundum ASDs occur sporadically, complicating identifi-
cation of possible causal genes. Nevertheless, several genes 
underlying ASDII have been identified, including transcrip-
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tion (co-)factor encoding genes such as GATA4, NKX2.5, 
and TBX5, and sarcomeric protein encoding genes such as 
ACTC1, MYH6 and MYH7. Secundum ASDs associated 
with atrioventricular block are linked to NKX2.5 mutations 
[6, 7]. Although a proportion of secundum ASDs are thus 
attributable to single-gene defects, its generally sporadic 
occurrence underlines a multifactorial causal mechanism, 
involving multiple susceptibility genes and environmental 
factors [8]. Nevertheless, with familial occurrence of ASDII, 
cardiogenetic testing is worth consideration as this might 
identify a known gene mutation, prompt evaluation of and 
earlier diagnosis in relatives, and aid genetic counselling.
Pathophysiology
The direction and magnitude of flow through an ASDII 
depends on defect size and the relative compliance of the 
left and right heart chambers. Initial left-to-right shunting 
results from the greater compliance of the right ventricle 
and right atrium, relative to the left heart chambers. A hae-
modynamically significant shunt causes right-sided volume 
overload [9]. Resultant right ventricular (RV) enlargement 
shifts the interventricular septum toward the left ventricle 
during diastole. This impairs left ventricular (LV) filling, 
leading to reduced LV stroke volume and cardiac output, 
and increased left-to-right shunting [10]. A longstanding 
shunt results in reduced RV compliance, increased right-
sided pressures and reduced left-to-right shunting. This can 
culminate in RV failure. Pulmonary vascular disease and 
pulmonary arterial hypertension (PAH) develop in a minor-
ity of patients, predominantly in females. Its aetiology is 
likely multifactorial, and not dependent on shunt size and 
duration alone. Eventually, pulmonary pressures can reach 
(supra)systemic levels, causing reversal of the intracardiac 
shunt: Eisenmenger physiology [3, 11].
Natural history and presenting symptoms
Patients with an isolated ASDII often remain asymptom-
atic during childhood and adolescence. However, most 
will become symptomatic from the third or fourth decade, 
and life expectancy is reduced overall [12]. Common ini-
tial symptoms are exercise intolerance and fatigue, which 
may be aggravated by a supraventricular tachycardia (SVT). 
SVTs are not infrequently the first clinical manifestation of 
an ASDII in patients over 40 years [13]. Eventually, right-
sided heart failure can develop, often with mild to moder-
ately elevated pulmonary arterial pressure (PAP) [12, 14]. 
Severe PAH, with possible progression to Eisenmenger 
physiology, ensues in a minority of patients [11]. Occasion-
ally, a suspected paradoxical systemic thromboembolism 
initially raises the suspicion of an ASDII being present [15].
Diagnostic work-up
Key findings of RV volume overload are RV heave, wide 
and fixed splitting of the second heart sound and a systolic 
pulmonary flow murmur. The ECG typically shows an rsR’ 
pattern in the right precordial leads and right QRS-axis devi-
ation. Both reflect RV hypertrophy. An early notch on the R 
wave in the inferior leads, called crochetage, is 92–100 % 
specific for ASDII when present in all three leads (Fig. 1) 
[16]. The chest X-ray may show enlargement of the right 
heart chambers and both central and peripheral pulmonary 
vasculature.
Transthoracic echocardiography (TTE) is the primary 
imaging modality for the diagnosis of an ASDII and assess-
ing its haemodynamic consequences. RV volume overload, 
reflected by RV enlargement and diastolic flattening and par-
adoxical systolic movement of the interventricular septum, 
indicates a significant shunt [10]. RV and PA pressures are 
estimated from the peak tricuspid regurgitation jet velocity. 
When TTE is inconclusive, contrast echocardiography can 
confirm the presence of an interatrial shunt. Transoesopha-
geal echocardiography (TEE) is required for determining 
the feasibility of transcatheter closure (See ‘Closure strat-
egy and post-procedural follow-up’ below) [17]. Referral to 
an adult congenital heart disease (ACHD) centre for further 
imaging is indicated when interatrial shunting or RV over-
load is recognised, but cannot be explained.
Cardiac magnetic resonance imaging (MRI) can help 
clarify the morphology of the defect, and is the gold stan-
dard for measurement of ventricular volume and function 
[18, 19]. Cardiac computed tomography (CT) provides an 
alternative in patients with contraindications to MRI [20]. 
Diagnostic catheterisation is only indicated when the possi-
bility of closure is uncertain in patients with high estimated 
PAP on echocardiography, to assess (reactivity of) pulmo-
nary vascular resistance (PVR) [9, 11].
Defect closure
Indications and contraindications for defect closure
Unless severe and irreversible PAH is present, patients with a 
haemodynamically significant shunt (i.e. one that causes RV 
enlargement) should undergo ASDII closure, irrespective of 
age and symptoms (Fig. 2) [21–23]. Haemodynamically 
insignificant ASDs do not require closure. Such patients 
should be followed conservatively, with repeat echocardiog-
raphy every 2–3 years, as shunt size may increase due to 
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evaluated in ACHD centres, as they may require invasive 
pre-interventional testing and treatment [9].
Closure strategy and post-procedural follow-up
Surgical repair of secundum ASDs is an effective proce-
dure with practically no perioperative mortality and mini-
mal morbidity, although the latter is somewhat higher in 
elderly patients [25]. Pericardial or synthetic patch closure 
is preferred over a direct suture, and generally completely 
terminates the shunt. Minimally invasive techniques have 
improved cosmetic outcomes, while maintaining the safety 
and efficacy of the traditional sternotomy [26]. Postoperative 
follow-up should include ECG surveillance for SVTs, and 
echocardiographic assessment of residual shunting, RV size 
and function and PAP. Subsequent annual follow-up is rec-
ommended for patients with an ASDII repaired in adulthood, 
who have or develop SVTs, PAH, ventricular dysfunction or 
valvular lesions. Current guidelines state that regular follow-
up is not required for patients repaired under the age of 25 
without relevant complications or residuae [9]. However, 
recent studies, and yet unpublished results from our own 
institution, show that even patients with early closure remain 
at risk of developing PAH late after closure [4, 27, 28]. This 
indicates that at least sporadic follow-up (i.e. once every 5 
years) is indicated in all patients with a closed ASDII.
Transcatheter device closure is generally the treatment of 
choice nowadays. It provides similar efficacy and haemo-
dynamic benefits, but reduced complication rates and dura-
tion of hospital stay compared with surgery, especially in 
older patients [29]. Secundum ASDs > 38 mm in diameter, 
those with inadequate septal rims for device anchorage, and 
those in which the device would interfere with atrioventric-
ular valve function or venous drainage are not eligible and 
referred for surgical closure [17]. In selected adult patients, 
the closure rate of single defects is 96 %, and occurrence of 
major periprocedural complications is < 1 % [30]. Endocar-
ditis prophylaxis is required during the first 6 months after 
device closure, as is antiplatelet therapy (aspirin 100 mg) 
[31]. Although rare, late complications, including device 
embolisation, erosion through the atrial wall or aortic root 
reduction in LV compliance associated with systemic hyper-
tension and/or coronary artery disease. When a paradoxical 
embolism is suspected, or the rare orthodeoxia-platypnoea 
syndrome is documented, closure is indicated regardless of 
shunt size [9, 15, 24].
PAH is not an absolute contraindication for defect closure 
[3]. Although estimation of PAP on echocardiography is 
usually sufficient, a diagnostic catheterisation to determine 
(reactivity of) PVR is indicated in selected patients. Closure 
is indicated if PVR is < 5 Wood units (WU). If the PVR is 
≥ 5 WU, closure can still be considered if the pulmonary-
to-systemic flow ratio is > 1.5 and PVR or PAP is less than 
two-thirds of the systemic levels or reactive to a pulmonary 
vasodilator challenge or targeted pretreatment. Patients with 
severe and irreversible PAH are not eligible for closure, as 
the ASDII is then physiologically needed for RV decom-
pression. Similarly, defect closure is contraindicated in case 
of significant LV dysfunction, as it then decompresses the 
LV. Thus, patients with PAH or poor LV function should be 
Fig. 1 a ECG of a 38-year-old woman with an ASDII. Mild right-axis 
deviation, rsR’ pattern in lead V1 reminiscent of a partial right bundle 
branch block. There is no further evidence of right ventricular hyper-
trophy. b Detail of lead aVF from an ECG of a 31-year-old man with 
an ASD, showing a notch on the R wave: crochetage
 
Fig. 2 Flow diagram of the factors involved in the decision concern-
ing defect closure in adults with an ASDII. RV right ventricle, PAP 
pulmonary artery pressure, PE paradoxical embolism, OPS orthode-
oxia-platypnoea syndrome, PVR pulmonary vascular resistance, Qp/
Qs pulmonary-to-systemic flow ratio, WU Woods unit, SVR systemic 
vascular resistance. *either at baseline or after pulmonary vasodila-
tor challenge or targeted pretreatment. **unless severe left ventricular 
dysfunction and/or mitral insufficiency are present. ¥ class of recom-
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tion in RA and RV size. The remodelling process and asso-
ciated increase in cardiopulmonary function commence 
immediately after closure and continue for several years 
[10, 35, 36]. Decreased RV volume improves ventricular 
interaction and LV filling. Subsequent increase in LV stroke 
volume and cardiac output is probably the main mechanism 
behind the improvement of exercise capacity after closure. 
These effects occur in patients of all ages, both symptom-
atic and asymptomatic. Although normal exercise capacity 
is reached in the majority, it may remain subnormal in those 
with poor cardiopulmonary function prior to closure [10]. 
This supports timely closure of sizeable secundum ASDs, 
regardless of age and symptoms.
Pulmonary hypertension. After ASDII closure in child-
hood or adolescence, PAH development later in life is 
unlikely, although not completely obviated [4, 27, 28, 37]. 
Among untreated adults, older age, greater defect size and 
female sex are associated with a greater frequency of PAH. 
Provided that pulmonary vascular disease has not progressed 
irreversibly, device closure can safely and effectively reduce 
PAP. Higher PAP and younger age are associated with a 
greater chance and magnitude of reduction in PAP. How-
ever, normalisation of PAP occurs less frequently with more 
severe PAH [3]. Moreover, if closure is performed late in 
life, the chance of PAH developing thereafter is increased 
[4]. These data strengthen the rationale for early closure.
Patients with an ASDII, open or closed, and PAH should 
be referred to an ACHD centre. As their haemodynamic 
and obstruction of venous drainage, necessitate follow-up 
(Fig. 3) [32]. However, consensus regarding frequency 
and duration of follow-up after device closure is lacking. 
It seems prudent to follow all adult patients regularly dur-
ing the first year (at 1, 6 and 12 months), and periodically 
thereafter. Those treated after the age of 40, and those with 
residual shunts, elevated PAP or documented dysrhythmias 
should have regular follow-up at an ACHD centre for 2 
years, and every 2–4 years thereafter [9]. As stated above, 
all patients should probably remain under follow-up.
The most commonly used devices, composed of syn-
thetic material and metallic wires (Fig. 4), induce fibrous 
encapsulation and neo-endothelialisation that eventually 
renders them functionally obsolete. However, the risk of 
long-term device-related complications such as erosion, 
device embolisation and nickel allergy remains [32]. Fur-
thermore, left atrial access for treatment of atrial dysrhyth-
mias or mitral valve disease might be obstructed, although 
this is not necessarily an issue (See ‘Supraventricular 
tachycardias’ under ‘Effects of defect closure’ below). The 
biodegradable BioSTAR implant (NMT Medical, Boston, 
MA) consists of collagen on a metal framework, is almost 
entirely absorbed after tissue overgrowth and thus poten-
tially reduces the risk of late device-related complications. 
Early results indicate safe and effective ASDII closure can 
be achieved with this device [33]. However, recent results 
indicate a high residual shunt rate (30 %) after 2 years [34]. 
Whether the potential for complications is indeed reduced, 
and what the place of biodegradable devices in ASDII treat-
ment should be, remains to be determined.
Effects of defect closure
Cardiac remodelling and exercise capacity. Closure of the 
ASDII results in right-sided volume unloading and reduc-
Fig. 3 Transthoracic echocardiogram from a patient with an ASDII, 
showing clear left-to-right shunting through an open defect (small 
white arrow) and right-atrial enlargement. The previously implanted 
closure device has embolised to the left ventricle (large white arrow)
 
Fig. 4 Synthetic ASDII closure device, the Amplatzer Septal Occlud-
er (AGA Medical Corporation, Plymouth, MN), which was retracted 
after attempted implantation. The metal wires and synthetic meshwork 
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Sports participation, diving and high altitude
The basis for recommendations regarding the safety of 
competitive sports participation is the individual patients’ 
abilities, haemodynamics and risk of decompensation or 
dysrhythmias. Nevertheless, general recommendations 
can be given. Evaluation should include a comprehensive 
history and physical examination, ECG, chest X-ray, TTE 
and exercise testing. Before or from 6 months after defect 
closure, asymptomatic patients with normal PAP can par-
ticipate in all sports, while restriction to low-intensity sports 
is indicated when PAH is present. Eisenmenger physiology 
precludes sports participation. In the presence of symp-
tomatic dysrhythmias, second-degree or third-degree heart 
block or ventricular dysfunction, individual evaluation and 
exercise prescription are indicated, for which we refer to the 
current guidelines [45].
Scuba diving carries the risk of developing decompres-
sion illness (DCI), which results from gasses coming out of 
solution into bubbles in blood and tissue upon ascent from 
a dive. Although absolute risk remains low, divers with an 
interatrial communication are at increased risk for major 
neurological DCI [46]. The presumed mechanism is para-
doxical embolisation of venous gas bubbles to the systemic 
arterial circulation. The association between interatrial 
shunts and neurological DCI has mainly been studied in 
divers with a patent foramen ovale, but the same principles 
apply to ASDII. Defect closure might prevent the occur-
rence of neurological DCI in divers, but this was shown in 
only one small prospective study [47]. Based on the above, 
screening for an interatrial shunt may be indicated in div-
ers that have developed DCI. When present, closure of the 
interatrial defect may prevent occurrence of major DCI, but 
the evidence is scarce and abstinence from diving might be 
advisable.
Regardless of health status, residing at high altitude 
exposes the individual to lower environmental partial oxy-
gen pressures and lower arterial oxygen tensions, with the 
risk of maladaptation and height-related diseases. These 
issues should be addressed in pretravel counselling [48]. 
Evidence-based recommendations for stays at high altitude 
in adult ASDII patients are not available. However, patients 
with uncomplicated defects should not require additional 
assessment. In contrast, patients with PAH or cyanosis 
require echocardiographic assessment of RV function and 
PAP, as well as cardiopulmonary exercise testing. At high 
altitude, hypoxic pulmonary vasoconstriction raises PVR 
resulting in persistent elevation of PAP. Consequently, RV 
workload and right-to-left shunting increase, predispos-
ing these patients to RV failure, severe hypoxaemia and 
the development of high altitude pulmonary oedema [48]. 
Cyanotic patients with coexisting anaemia, ventricular dys-
function or low exercise capacity should avoid stays at high 
balance is readily disrupted, planned medication changes 
or interventions should be discussed with their specialised 
caregiver. Moreover, the prescription of disease-target-
ing therapy such as the endothelin antagonist bosentan is 
restricted to these specialists. When PAH develops late after 
closure, other non-shunt-related risk factors should be ruled 
out to appropriately target therapy [9, 11].
Supraventricular tachycardias are common late in the 
natural history of an ASDII [13, 21], and defect closure is 
of preventive, but not therapeutic value in this regard. Thus, 
SVTs are not a decisive indication for defect closure in the 
absence of other symptomatology. Among patients who 
underwent closure in childhood or early adolescence, SVTs 
are rare during long-term follow-up [37]. Those with a his-
tory of SVT or PAH and those treated later in life, especially 
at ages over 40 years, remain at increased risk [13, 21, 38]. 
Paroxysmal SVTs may not recur after closure, but chronic 
SVTs usually persist. Concomitant Maze procedure during 
surgery or electrical cardioversion at the time of device clo-
sure is worth consideration [9, 38, 39]. Class III antiarrhyth-
mic agents may be the most effective in maintaining sinus 
rhythm after cardioversion in these patients [40].
In patients developing symptomatic drug-resistant atrial 
fibrillation after closure, catheter ablation is an effective 
treatment. Perceived difficulty in obtaining prerequisite left 
atrial access may discourage its utilisation in patients with 
an ASD closure device. However, intracardiac echocardiog-
raphy-guided transseptal catheter ablation is safe and effec-
tive, even in the presence of a closure device. Left atrial 
access is generally achieved through residual native septum. 
In the absence of a suitable native septal area, direct punc-
ture of the Amplatzer device is possible, at the cost of greater 
technical difficulty and longer procedural time. Although no 
long-term data are available, complications and residual 
shunts are rare with both approaches [41]. Retrograde aortic 
access using remote magnetic navigation may provide an 
alternative approach [42].
Survival. Closure confers a survival benefit in all ASDII 
patients, regardless of age [22]. However, eventual life 
expectancy is dependent on age at closure. An often-cited 
study into the long-term outcome after surgical repair 
showed normal survival after closure under the age of 25. 
In contrast, patients operated later in life, especially at ages 
over 40, experienced increased mortality [21]. Percutaneous 
closure can be expected to confer a survival benefit at least 
similar to that reported in surgical series, but a randomised 
comparison to prove and quantify this benefit would be 
unethical in the current era. The excellent survival of the 
contemporary ASDII population is confirmed by unpub-
lished data from our own institution which suggest normal 
overall life expectancy, although this appears to be restricted 
to the female majority [43, 44].
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Women with an open ASDII not complicated by PAH 
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